GPT and glioblastoma: A phase I and II trial testing autologous DC-tumor vaccine therapy in both recurrent and newly diagnosed GBM patients achieved a median survival of 525 days with lymphopenia and reversible elevations in AST/ALT as the only two reported adverse effects (Chang et al., 2011).